COVID-19 vaccine Sinopharm gains WHO emergency approval

By Christine Fabro

The World Health Organization (WHO) granted emergency use for the Sinopharm COVID-19 vaccine yesterday (May 7) to be rolled out globally – the first Chinese-made vaccine to gain WHO approval.

According to Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products, this additional listing has the potential to “rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk.”

The vaccine has an efficacy rate of 79% for symptomatic and hospitalized cases, and is recommended for adults 18 years and older, administered in a two-dose schedule.

The Sinopharm COVID-19 vaccine is also the first vaccine that will carry a vaccine vial monitor, which indicates whether the vaccine can be safely used and its easy storage requirements makes it highly suitable for low-resource settings.

WHO previously listed Pfizer/BioNTech, AstraZeneca/Oxford, Serum Institute of India, Janssen, and Moderna vaccines for emergency use. –WHO/CF-RIR

Popular

‘Bawat Bayan Makikinabang’: PBBM assures sustained LGU funding

By Brian Campued Recognizing the challenges faced by local government units (LGUs), such as limited resources and lack of support from the national government, President...

PBBM, AZEC affirm energy security ties, renewable energy support

By Brian Campued President Ferdinand R. Marcos Jr. underscored the importance of cooperation between the Philippines and Japan in strengthening energy security measures, as tensions...

PBBM inaugurates P1B irrigation project in Leyte

By Sarwell Meniano | Philippine News Agency President Ferdinand R. Marcos led the inauguration of the P1.1 billion Hibulangan Small Reservoir Irrigation Project (SRIP) in...

PBBM brings aid to Eastern Visayas, advances whole-of-gov’t approach

By Ruth Abbey Gita-Carlos | Philippine News Agency President Ferdinand R. Marcos Jr. on Thursday led the rollout of government assistance and development initiatives in...